Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Feb;10(3):1043-1056.
doi: 10.1002/cam4.3692. Epub 2020 Dec 31.

The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis

Hanqing Liu  1 , Dan Yang  2 , Xinyue Chen  1 , Zhihong Sun  1 , Yutong Zou  3 , Chuang Chen  1 , Shengrong Sun  1
Affiliations
Meta-Analysis

The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis

Hanqing Liu et al. Cancer Med. 2021 Feb.

Abstract

Background: The relationship between cancer and COVID-19 has been revealed during the pandemic. Some anticancer treatments have been reported to have negative influences on COVID-19-infected patients while other studies did not support this hypothesis.

Methods: A literature search was conducted in WOS, PubMed, Embase, Cochrane Library, CNKI and VIP between Dec 1, 2019 and Sept 23, 2020 for studies on anticancer treatments in patients with COVID-19. Cohort studies involving over 20 patients with cancer were included. The characteristics of the patients and studies, treatment types, mortality, and other additional outcomes were extracted and pooled for synthesis. RRs and forest plots were adopted to present the results. The literature quality and publication bias were assessed using NOS and Egger's test, respectively.

Results: We analyzed the data from 29 studies, with 5121 cancer patients with COVID-19 meeting the inclusion criteria. There were no significant differences in mortality between patients receiving anticancer treatment and those not (RR 1.17, 95%CI: 0.96-1.43, I2 =66%, p = 0.12). Importantly, in patients with hematological malignancies, chemotherapy could markedly increase the mortality (RR 2.68, 95% CI: 1.90-3.78, I2 =0%, p < 0.00001). In patients with solid tumors, no significant differences in mortality were observed (RR 1.16, 95% CI: 0.57-2.36, I2 =72%, p = 0.67). In addition, our analysis revealed that anticancer therapies had no effects on the ICU admission rate (RR 0.87, 95% CI: 0.70-1.09, I2 =25%, p = 0.23), the severe rate (RR 1.04, 95% CI: 0.95-1.13, I2 =31%, p = 0.42), or respiratory support rate (RR 0.92, 95% CI: 0.70-1.21, I2 =32%, p = 0.55) in COVID-19-infected patients with cancer. Notably, patients receiving surgery had a higher rate of respiratory support than those without any antitumor treatment (RR 1.87, 95%CI: 1.02-3.46, I2 =0%, p = 0.04).

Conclusions: No significant difference was seen in any anticancer treatments in the solid tumor subgroup. Chemotherapy, however, will lead to higher mortality in patients with hematological malignancies. Multicenter, prospective studies are needed to re-evaluate the results.

Keywords: COVID-19; cancer; chemotherapy; hematological malignancy.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interest.

Figures

FIGURE 1
FIGURE 1
Flow chart of study selection
FIGURE 2
FIGURE 2
Forest plot for the association between antitumor treatments and risk of mortality in cancer patients with COVID‐19 using random‐effects model
FIGURE 3
FIGURE 3
Forest plot for the association between antitumor treatments and the severe/critical rate in cancer patients with COVID‐19 using fixed‐effects model
FIGURE 4
FIGURE 4
Forest plot for the association between antitumor treatments and the mortality rate in solid tumor patients with COVID‐19 using random‐effects model
FIGURE 5
FIGURE 5
Forest plot for the association between antitumor treatments and the mortality rate in hematological malignancies patients with COVID‐19 using random‐effects model
See this image and copyright information in PMC

References

    1. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nature Microbiol. 2020;5(4):536‐544. - PMC - PubMed
    1. World Health Organization . Coronavirus disease (COVID‐19) pandemic. https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019. Accessed 17 Oct 2020.
    1. WHO International Agency for Research on Cancer . Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. https://www.who.int/cancer/PRGlobocanFinal.pdf. Accessed 24 July 2020.
    1. Yu J, Ouyang W, Chua MLK, Xie C. SARS‐CoV‐2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108‐1110. - PMC - PubMed
    1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335‐337. - PMC - PubMed

Publication types

MeSH terms

Substances